2023
Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
Masi G, Pham M, Karatz T, Oh S, Payne A, Nowak R, Howard J, Guptill J, Juel V, O'Connor K. Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals Of Clinical And Translational Neurology 2023, 10: 825-831. PMID: 36924454, PMCID: PMC10187728, DOI: 10.1002/acn3.51761.Peer-Reviewed Original Research
2022
A prospective natural history study and biorepository for patients with myasthenia gravis (EXPLORE-MG2) (P6-13.005)
Guptill J, Nowak R, Guidon A, Howard J, Soliven B, Hammett A, Sheldon B, Li Y, Meece T, Aban I, Cutter G, Kaminski H. A prospective natural history study and biorepository for patients with myasthenia gravis (EXPLORE-MG2) (P6-13.005). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2269.Peer-Reviewed Original Research
2021
Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis (1417)
Benatar M, Breiner A, Bril V, Nowak R, Dunn I, Jacobs A. Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis (1417). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.1417.Peer-Reviewed Original ResearchVivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157)
Guptill J, Antozzi C, Bril V, Gamez J, Meuth S, Blanco J, Nowak R, Quan D, Sevilla T, Szczudlik A, Hegarty B, Jouvin M, Jin J, Arroyo S. Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.2157.Peer-Reviewed Original Research
2019
P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin
Genge A, Jacob S, Murai H, Utsugisawa K, Nowak R, Wiendl H, Fujita K, O’Brien F, Howard J. P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s20-s21. DOI: 10.1017/cjn.2019.126.Peer-Reviewed Original ResearchIntravenous immunoglobulinMyasthenia gravisAnti-acetylcholine receptor antibody-positive refractoryRefractory myasthenia gravisOpen-label extensionPlacebo-controlled studyMeaningful clinical improvementExperienced exacerbationRescue therapyClinical improvementEighteen patientsMore patientsSubgroup analysisEculizumabPatientsPlaceboExacerbationRelevant improvementGravisPhase 3Status changesInterim dataImmunoglobulinPrevious reportsMeaningful responses